Trial Profile

A Phase II Study of Anti-CD3 x Anti-HER2/Neu Armed Activated T Cells for Patients With HER2/Neu (0, 1+ or 2+) Metastatic Breast Cancers.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 27 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD3-anti-HER2-activated T-cells (Primary) ; Cyclophosphamide
Indications Advanced breast cancer; Triple negative breast cancer
Focus Therapeutic Use

Most Recent Events

29 Nov 2022 Status has been changed to discontinued.
04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
19 May 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com